Addendum D
80 Columbia Street • PO Box 910 • Stevenson, WA 98648
————————————————————————————————————
•Medical Doctor Degree from New York University School of Medicine •Immunologist
and Board Certified Urological Surgeon. •30 years of drug research and development
experience with various pharmaceutical companies including Bristol-Myers International,
Mead-Johnson Pharmaceutical Co. and E.R. Squibb. •An accomplished executive with
domestic and international experience. •Practiced in the formation of strategic alliances,
key partnership development and high stake negotiations. •Successfully executed
acquisitions of breakthrough medical technology, in conjunction with formation, funding
and launch of several corporations. • Co-founder of Medco Research Inc., a NYSE
biopharmaceutical company acquired by King Pharmaceutical Inc. •Founder of Axonyx
Inc., acquired by TorreyPines Therapeutics, Inc. •Founder of Total Nutraceutical
Solutions, Inc.; design and development of natural organic antioxidant mushroom
products to be used as nutritional supplements in humans and animals •Founder and
President of Northwest Medical Research Partners, Inc., a company specializing in the
identification and acquisition of breakthrough pharmaceutical and nutraceutical products.
Total Nutraceutical Solutions, Inc. CEO and Chairman of the Board;
A Nutraceutical company with a focus on discovering, formulating and marketing
products composed primarily of organic natural mushroom compounds that contain
bioactive nutrients for potential health benefits. TNS develops production and analytic
technologies for food and nutritional supplements composed primarily of mushrooms and
their mycelia biomasses. Novel clinical models and biomarkers are used to show
nutritional and clinical efficacy of our products. In addition to preventative health care
formulations and nutritional approaches to a wide variety of human conditions and
illnesses, TNS also develops and acquires break through nutritional tools and products in
the fields of animal husbandry and livestock feeds.
Research and formulation of bioactive mushroom Nutraceutical products with anti-
oxidant/anti-inflammatory activities for humans and animals.
Design and development of biomarker assays to monitor human and animal clinical
responses to nutritional supplementation
United States Use Patent filings related to increased biologic survival with the use of
Oxis International, Inc. Foster City, CA President, CEO, and Chairman of the Board;
A company that develops technologies and products to research, diagnose, treat and
prevent diseases associated with damage from free radicals and reactive oxygen species
and the increased inflammation that accompanies oxidative stress.
Engineered and Executed Manufacturing and/or Supply Agreements with Cambridge
Major Laboratories Inc., Minitube of America and Golden Gourmet Mushrooms Inc.
Negotiation, design and submission with Duke University of joint bioterrorism drug
research and development grant protocols to United States BioShield/Barda program
Northwest Medical Research Partners, Inc., Stevenson, WA Founder and President
A company specializing in the identification and acquisition of breakthrough
pharmaceutical and nutraceutical products.
Identification, acquisition and funding of Alzheimer’s disease drug portfolio from The
Identification and acquisition of preclinical Beta-amyloid Alzheimer’s disease drug
portfolio and intellectual property from Department of Pathology, New York University
School of Medicine; successfully out licensed to Serono Inc, Geneva, Switzerland
Facilitated, executed and financed Research and Development agreement with
Department of Food Science, Pennsylvania State University; identified key bioactive
nutrients within mushrooms and discovered new composition of matter substance
including filing of patents. Axonyx, Inc., New York, New York Founder and CEO
A biotechnology company specializing in the development of pharmaceutical compounds
for the treatment of Alzheimer’s Disease and related central nervous system conditions.
NASDAQ listed company merged with TorreyPines Therapeutics, Inc. (TPTX)
In licensing of preclinical and clinical Alzheimer’s disease drug portfolios
Total Nutraceutical Solutions Inc., Spartanburg SC (TNUS: OTC.BB) Director
Golden Gourmet Mushrooms, Inc. / Mushroom Matrix, San Marcos, CA Scientific Consultant
A company performing research and development, and sales and marketing, of
specialized exotic natural mushroom powders/capsules with potent anti-oxidant/anti-
LPath Therapeutics Inc. San Diego CA (LPATH: OTC.BB) Consultant
A biotechnology company focused on the discovery and development of lipid-based
therapeutics, an emerging field of medical science whereby lipids are targeted to treat
human diseases. Arbios Technologies, Los Angeles CA (ABOS: OTC.BB) Director
A company engaged in the discovery, acquisition and development of proprietary liver
assist devices and new technologies useful in the diagnosis and treatment of acute liver
Regent Assisted Living, Inc., Portland Oregon Director
A Company specializing in building care centers for Assisted Living and clients with
Medco Research, Inc., Research Triangle Park, North Carolina Director
A company engaged in the acquisition, research and development of proprietary human
health care products, focused primarily in the area of cardiovascular disease.
Columbia Gorge Interpretive Center, Stevenson WA Director
A museum concerned with the preservation of history and culture of the Columbia River
New York University School of Medicine, New York, New York Board of Governors, Alumni Association State of California Advisor and Medical Examiner in Forensic Urology
Personal Injury, Worker’s Compensation Plaintiff and Defendant specializing in Bladder
Dysfunction, Male Sexual Dysfunction, Hernia, Inguinal and Abdominal, Lumbosacral
Injuries and Associated Bladder and Sexual Problems.
Mead-Johnson Pharmaceutical Co., Evansville, Indiana Lecturer
Antibiotic Research, Development and Clinical Application, Male Sexual Dysfunction Bristol Meyers International, Mead-Johnson Pharmaceutical Co., Medco Research, Inc. E.R. Squibb Consultant
Clinical and Pharmaceutical Research Consultant
U.C.L.A. Medical Center, Dept. of Immunology/Urology, Los Angeles CA Consultant
Bladder Cancer project, BCG Immunotherapy
EDUCATION
New York University School of Medicine, New York New York
POSITIONS IN MEDICINE U.C.L.A. Medical Center, Los Angeles CA Research Fellowship – Immunology
Dr. Paul Terasaki, Department of Surgery, HLA Typing Research, in-vitro and in-vivo
Mt. Sinai Hospital, New York New York Intern Resident in Surgery
National Institute of Health, Bethesda Maryland Surgeon
USPHS, Immunology Section, Laboratory of Microbiology, National Institute of Dental
Research performing research work with Ralph Snyderman, M.D. on 3rd and 5th
U.C.L.A. Medical Center, Los Angeles CA Resident, Division of Urology
Dept. of Medical Microbiology and Immunology School of Medicine Los Angeles CA Postdoctoral Scholar
U.C.L.A. Medical Center, Los Angeles, CA Lecturer, Division of Urology Clinical Instructor and Visiting Surgeon Division of Urology and Dept. of Surgery
TEACHING POSTIONS
U.C.L.A. Medical Center, Los Angeles, CA Visiting Surgeon, Division of Urology and Dept. of Surgery
Cedars-Sinai Medical Center, Los Angeles CA Clinical Instructor, Pediatric Urology, Dept. of Pediatrics
Samuel Soifer Memorial Prize for Outstanding Work in Urology
Clinical Research on Duricef (antibiotic)
American College of Emergency Physicians
Clinical Research on Duricef (antibiotic)
American Urological Association, Western Section
Research and Development of Condranol (Antiatherosclerotic Drug)
HISTORICAL MEMBERSHIPS
The American Association of Immunologists
American Association for the Advancement of Science
American Federation for Clinical Research
Kidney Foundation of Southern California
American Urological Association - Western Section
EXPERIENCE WITH NEW DRUG INVESTIGATION
1. Sulfamethoxazole-Trimethoprim (Bactrim) in chronic urinary tract infection, 1972 -
1974; Harbor General Hospital, Torrance, California, Hoffman-La Roche, Inc.
2. BCG therapy in patients with genitourinary carcinoma, 1973 to 1978. Departments of
Urology a nd Immunology, U .C.L.A. Medical C enter, L os Angeles, C alifornia.
National Bladder Cancer Project, Public Health Service; Grant #CA 16880. US FDA
3. Effects of Bacillus Calmette-Guerin (BCG) on the dog bladder, Invest. Urol. 12:423,
4. Cefadroxil (D uricef) - A n ew s afe ef fective d rug i n t he t reatment o f urinary t ract
infections, 1977 - 1979; C linical Research S tudy, M ead-Johnson P harmaceutical
5. Cefadroxil (D uricef) - A onc e-a-day oral c ephalosporin f or t he t reatment of a cute
cystitis, 1977 - 1979; C linical Research S tudy, M ead-Johnson P harmaceutical
6. Condranol (Chondroitin sulfate A and B), clinical efficacy in the prevention of post-
operative de ep ve in t hrombosis. C edars-Sinai M edical C enter, Biomed R esearch,
Inc., Los Angeles, California, 1979 - 1981.
7. Velosef / Ceclor clinical study in acute cystitis, E.R. Squibb & Sons, Inc. 1980.
8. Papaverine, clinical efficacy in impotence. Los Angeles, California, 1985 - 1986.
9. Y-Bron, clinical efficacy in impotence, 1988 - 1989.
10. Male Delay Spray, clinical efficacy in premature ejaculation, Los Angeles, California
11. Adenocard™, f or c onversion t o nor mal s inus r hythm i n pa tients w ith p aroxysmal
supraventricular tachycardia (PSVT), 1978-1993. US FDA approved.
12. Adenoscan™, a pharmacologic stress agent used for coronary vasodilation in patients
unable to exercise adequately. 1978-1993. US FDA approved.
13. Phenserine, an acetylcholinesterase inhibitor having potential to provide symptomatic
improvement a nd tr eat the p rogression o f mild to mo derate Alzheimer’s d isease.
EXPERIENCE WITH MEDICAL DEVICE INVESTIGATION
1. EZ Detect Occult Blood Test, NMS Pharmaceutical, Inc., Newport Beach, California,
2. StrutR (Companion-EPDR) - A n ew alternative in th e d iagnosis a nd tr eatment o f
impotence: I MS, I nc., C ompanion Medical Products, Inc., Los A ngeles, a nd S an
Published Articles Available on Request
Umgang mit psychiatrischen Notfällen 1. Ausgangslage Im Notfalldienst wird der Notfallarzt häufig auch mit psychiatrischen Notfällen konfrontiert. Es stellen sich dabei schwierige diagnostische und therapeutische Fragen in einem oft komplizierten Umfeld. Zum eigenen Schutz bedarf es in einigen Situationen den Bezug von Drittpersonen oder der Polizei. Auch muss die Frage der Einwe
Working Group 4 Report - 2010 Report of the Working Group on the “Global Sickle Cell Disease Network” Chairs Isaac Odame , Hospital for Sick Children, Toronto Hani Atrash , Center for Disease Control, Atlanta Participants : Errol Alden , -American Academy of Pediatrics, Chicago Eiman Abdulramman , Atlanta, Georgia Margaret Bash , National Institute of Health, Bethes